Company name: Ultragenyx Pharmaceutical Inc.
Industry: Pharmaceuticals.
Location: Novato, California.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Solution/product: Ultragenyx is developing a sialic acid replacement therapy for treatment of the rare, progressive neuromuscular disease hereditary inclusion body myopathy. The disease is caused by a deficiency in sialic acid that causes muscles to slowly waste away, which causes many patients to need a wheelchair within 10 to 15 years of disease onset. Ultragenyx’s oral drug uses an extended-release formulation of sialic acid.
Money raised: $15.1 million in what appears to be a second closing of a $45 million series A announced last year.
How it will be used: Last month, Ultragenyx started a phase 2 study of UX-001 and said it expects results in 2013. A company representative did not return a call for details.
A second drug in the company’s pipeline, UX-003, is an enzyme replacement therapy for the rare genetic metabolic disorder Sly syndrome, which results from a deficiency of the enzyme beta-glucoronidase. It received orphan drug designation in February.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Investors: Existing investors include TPG Biotech, Fidelity Biosciences, HealthCap and Pappas Ventures.
Management team: Founder and CEO Emil Kakkis is the founder of BioMarin Pharmaceutical Inc., which saw three rare disease products approved during his tenure as CEO.
Market size: Although orphan drugs are intended to treat conditions with fewer than 200,000 patients, there’s been renewed interest in them as of late that’s included both startups and major players like GSK and Bristol-Myers Squibb. In 2011, the U.S. Food and Drug Administration approved a dozen new or reformulated products with orphan drug designation.
Competitors: Currently, treatment of HIBM is symptomatic. Researchers are working on a few different approaches to treatment including gene and stem cell therapies, but Ultragenyx appears to be the furthest along in development.
